Ceruloplasmin activity and iron chelation treatment of patients with Parkinson’s disease

Automation of o-dianisidine assay for ceruloplasmin activity analyses: usefulness of investigation in Wilson’s disease and in hepatic encephalopathy

(2014) Mariacristina Siotto et al.   JOURNAL OF NEURAL TRANSMISSION

Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease

(2013) David Devos et al.   ANTIOXIDANTS & REDOX SIGNALING

Regional siderosis: a new challenge for iron chelation therapy

(2013) Zvi Ioav Cabantchik et al.   Frontiers in Pharmacology

Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease

(2012) Scott Ayton et al.   ANNALS OF NEUROLOGY

The history of the research of iron in parkinsonian substantia nigra

(2012) Andrzej Friedman et al.   JOURNAL OF NEURAL TRANSMISSION

Ceruloplasmin Oxidation, a Feature of Parkinson's Disease CSF, Inhibits Ferroxidase Activity and Promotes Cellular Iron Retention

(2011) S. Olivieri et al.   JOURNAL OF NEUROSCIENCE

Intracellular labile iron

(2007) William Breuer et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY